Effectiveness of Rituximab and Its Biosimilar in Treating Adult Steroid-Dependent Minimal Change Disease and Relapse

被引：0
作者：
Shan, Hui Yi [1 ]
机构：
[1] Keck Sch Med Univ Southern Calif, Dept Med, Nephrol & Hypertens, Los Angeles, CA 90033 USA
来源：
CUREUS JOURNAL OF MEDICAL SCIENCE | 2023年 / 15卷 / 11期
关键词：
frequent relapses; steroid-dependent minimal change disease; rituximab biosimilar; ruxience; rituximab; minimal change disease;
D O I：
10.7759/cureus.49200
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Minimal change disease (MCD) is an important cause of nephrotic syndrome in adults. Its course is often complicated by frequent relapses and steroid dependence. Most of the treatment experience of MCD comes from management of pediatric patients rather than adult patients. In this report, the author describes successful experience of using rituximab (RTX) and its biosimilar, RTX-pvvr (ruxience), to treat steroid -dependent MCD and relapses in adult patients. This is the first report of using a RTX biosimilar to treat MCD. This case series demonstrates that RTX and ruxience are well-tolerated, efficacious treatment for managing adult patients with steroid-dependent MCD and relapses.
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy
    Kerstin Benz
    Jörg Dötsch
    Wolfgang Rascher
    Daniel Stachel
    Pediatric Nephrology, 2004, 19 : 794 - 797
  • [22] Amelioration of the adverse effects of prednisolone by rituximab treatment in adults with steroid-dependent minimal-change nephrotic syndrome
    Miyabe, Yoei
    Takei, Takashi
    Iwabuchi, Yuko
    Moriyama, Takahito
    Nitta, Kosaku
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2016, 20 (01) : 103 - 110
  • [23] Relapse during and after regular single-dose rituximab treatment in adult patients with steroid-dependent nephrotic syndrome
    Saito, Eiichiro
    Oura, Atsushi
    Kyo, Tetsuya
    Ishigaki, Shun
    Kamei, Hitomi
    Nakamura, Yuki
    Soma, Jun
    Nakaya, Izaya
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2024, 28 (11) : 1082 - 1089
  • [24] Amelioration of the adverse effects of prednisolone by rituximab treatment in adults with steroid-dependent minimal-change nephrotic syndrome
    Yoei Miyabe
    Takashi Takei
    Yuko Iwabuchi
    Takahito Moriyama
    Kosaku Nitta
    Clinical and Experimental Nephrology, 2016, 20 : 103 - 110
  • [25] Obinutuzumab is effective for the treatment of frequently-relapsing/steroid-dependent minimal change disease in adults
    Jin, Li
    Liu, Xueying
    Li, Huixian
    Dang, Xiangyun
    Wang, Zhigang
    Niu, Dan
    Zhang, Xiaotian
    Sun, Jiping
    Hao, Dapeng
    Lu, Wanhong
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 (08) : 1364 - 1367
  • [26] Extended infusion of rituximab combined with steroids is effective in inducing remission and reducing relapse in adult minimal change disease
    Liu, Diankun
    Zhou, Zhanmei
    Wang, Mengyi
    Nie, Sheng
    Li, Jun
    Hu, Bianxiang
    He, Wenjuan
    Wang, Guobao
    Ai, Jun
    BMC NEPHROLOGY, 2021, 22 (01)
  • [27] Extended infusion of rituximab combined with steroids is effective in inducing remission and reducing relapse in adult minimal change disease
    Diankun Liu
    Zhanmei Zhou
    Mengyi Wang
    Sheng Nie
    Jun Li
    Bianxiang Hu
    Wenjuan He
    Guobao Wang
    Jun Ai
    BMC Nephrology, 22
  • [28] Rituximab in Adult Minimal Change Disease and Focal Segmental Glomerulosclerosis
    Kronbichler, Andreas
    Bruchfeld, Annette
    NEPHRON CLINICAL PRACTICE, 2014, 128 (3-4): : 277 - 282
  • [29] The efficacy of rituximab in adult frequently relapsing minimal change disease
    King, Catherine
    Logan, Sarah
    Smith, Stuart W.
    Hewins, Peter
    CLINICAL KIDNEY JOURNAL, 2017, 10 (01) : 16 - 19
  • [30] Rituximab as Initial Therapy in Adult Patients With Minimal Change Disease
    Guan, Nan
    Zhang, Min
    Chen, Ruiying
    Xie, Qionghong
    Hao, Chuan-Ming
    KIDNEY INTERNATIONAL REPORTS, 2023, 8 (05): : 1102 - 1104
12345